Welcome!

Premium Advice
- My Services
- None
- Other Services
- Champion Funds
- Duke Street
- Global Gains
- Hidden Gems
- Income Investor
- Inside Value
- Million Dollar Portfolio
- Motley Fool Options
- Motley Fool Pro
- Pay Dirt
- Ready-Made Millionaire
- Rule Breakers
- Rule Your Retirement
- Stock Advisor
- *Get a Fool Credit Card

Help Join Now or

Updated: 12/1/2009 12:40 PM					Sponsored by:
	DOW	10468.63	123.79	1.20%
	S&P 500	1108.48	12.85	1.17%
	NASD	2176.64	32.04	1.49%

Graceway buys 3 Pfizer skin drug candidates

By Associated Press
July 2, 2009 | Comments (0)

Recs

0

Graceway Pharmaceuticals LLC said Thursday it agreed to buy two potential acne treatments and an anti-scarring drug candidate from Pfizer Inc.

The companies did not disclose terms of the sale.

Graceway said the two treatments for oily skin and acne are being tested on humans, with one in early stage trials and the other in mid stage trials. The third drug candidate is intended to reduce scarring from surgery, and is in preclinical development.

Pfizer will perform development and clinical service activities for the three drugs. The New York company said it did not see the drugs as key assets.

Bristol, Tenn.-based Graceway is a unit of GTCR Golder Rauner LLC.

In morning trading, Pfizer stock slid 36 cents, or 2.4 percent, to $14.54.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

DocumentId: 933453, ~/Articles/ArticleHandler.aspx, 12/1/2009 12:41:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.